6月13日，以色列生物制药公司乌龙制药（URGN）股票恢复交易后涨幅达63%。美国食品药品管理局（FDA）批准其新药Zusduri用于膀胱癌治疗。该公司致力于开发改善泌尿系统疾病护理的创新疗法，此获批标志着其在癌症治疗领域取得重要突破。
Source Link6月13日，以色列生物制药公司乌龙制药（URGN）股票恢复交易后涨幅达63%。美国食品药品管理局（FDA）批准其新药Zusduri用于膀胱癌治疗。该公司致力于开发改善泌尿系统疾病护理的创新疗法，此获批标志着其在癌症治疗领域取得重要突破。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.